We share our Insights on a regular basis.

Media Contacts

Terra Liddell: Chief Marketing Officer; Washington, DC; Email

Angela Robinson: Director of Branding and Communications; Washington, DC; Email

IP Updates

Unified Patent Court (UPC) Hub

2026

Articles

Preempting Surprise Injunctions in Germany and the UPC: Strategic Use of the Schutzschrift in Global Patent Litigation

March 27, 2026

Articles

Patent Ruling Shows Quiet Power of State-Law Bad-Faith Statutes

February 20, 2026

Articles

EPR Academy, Part 2 of 6: The EPR Process – From Request to Reexamination Certificate

December 5, 2025

IP Updates

Tenth Circuit Sides with Netflix in Tiger King Copyright Challenge

May 5, 2026

IP Updates

PIER Pilot Program - Synopsis

IP Updates

White House Releases National AI Legislative Framework

March 23, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Federal Circuit IP Blog

Federal Circuit Affirms § 102(b) Invalidity; Source Code Commands Are Not Hearsay

May 14, 2026

INCONTESTABLE® Blog

Supreme Court Recalibrates Contributory Copyright Liability

March 30, 2026

Recent Insights

to

Downloadable Media

Event Type

Hosting Organization

Finnegan-Hosted

Articles

Choice of Law in Patent Appeals: The Federal Circuit’s Issue-by-Issue Framework

Choice of Law in Patent Appeals: The Federal Circuit’s Issue-by-Issue Framework Choice of Law in Patent Appeals: The Federal Circuit’s Issue-by-Issue Framework

May/June 2026

IP Litigator

Articles

Section 337 After Lashify: Practical Implications for Non-U.S. Companies: What the Federal Circuit’s March 2025 Decision Means for Those Who Can Credibly Bring an ITC Case

Section 337 After Lashify: Practical Implications for Non-U.S. Companies: What the Federal Circuit’s March 2025 Decision Means for Those Who Can Credibly Bring an ITC Case Section 337 After Lashify: Practical Implications for Non-U.S. Companies: What the Federal Circuit’s March 2025 Decision Means for Those Who Can Credibly Bring an ITC Case

November/December 2025

IP Litigator

Articles

Structuring Patent Royalties to Avoid Unnecessary U.S. Customs Duties: Lessons from CBP Rulings

Structuring Patent Royalties to Avoid Unnecessary U.S. Customs Duties: Lessons from CBP Rulings Structuring Patent Royalties to Avoid Unnecessary U.S. Customs Duties: Lessons from CBP Rulings

May/June 2025

IP Litigator

Articles

Recovering for Foreign Sales on a U.S. Patent: The Global Implications of the Federal Circuit’s Recent Decision in Brumfield

Recovering for Foreign Sales on a U.S. Patent: The Global Implications of the Federal Circuit’s Recent Decision in Brumfield Recovering for Foreign Sales on a U.S. Patent: The Global Implications of the Federal Circuit’s Recent Decision in Brumfield

September/October 2024

IP Litigator

Articles

Using Statements from Foreign Patent Office Proceedings to Construe U.S. Patent Claims

Using Statements from Foreign Patent Office Proceedings to Construe U.S. Patent Claims Using Statements from Foreign Patent Office Proceedings to Construe U.S. Patent Claims

September/October 2023

IP Litigator

Articles

Finding Favorable Fora for Foreign Firms

Finding Favorable Fora for Foreign Firms Finding Favorable Fora for Foreign Firms

May 9, 2023

IP Litigator

IP Updates

Finnegan to Argue Before the Supreme Court on Behalf of Navy Veteran Finnegan to Argue Before the Supreme Court on Behalf of Navy Veteran

October 3, 2022

Articles

Out of the ITC in 100 Days

Out of the ITC in 100 Days Out of the ITC in 100 Days

May/June 2022

IP Litigator

Articles

As the Curtain Falls on CBM Review, What’s Next for Financial Institutions?

As the Curtain Falls on CBM Review, What’s Next for Financial Institutions? As the Curtain Falls on CBM Review, What’s Next for Financial Institutions?

March/April 2022

IP Litigator

Articles

A Retrospective on Myriad Genetics: What Makes Medical Diagnostics Patent-Eligible 8 Years Later?

A Retrospective on Myriad Genetics: What Makes Medical Diagnostics Patent-Eligible 8 Years Later? A Retrospective on Myriad Genetics: What Makes Medical Diagnostics Patent-Eligible 8 Years Later?

May/June 2021

IP Litigator

Articles

Appealing Institution Issues and Section 314(d) Appealing Institution Issues and Section 314(d)

July/August 2020

IP Litigator

Articles

The Role of Intrinsic Evidence in Construing Means-Plus-Function After Williamson The Role of Intrinsic Evidence in Construing Means-Plus-Function After Williamson

March/April 2020

IP Litigator